CSIMarket Company Name, Ticker, Customers, else..
 
Vaxcyte Inc   (NASDAQ: PCVX)
 
Price: $59.1100 $0.21 0.357%
Day's High: $60.20000076293945 Week Perf: -3.35 %
Day's Low: $ 58.22 30 Day Perf: -0.91 %
Volume (M): 847,898 52 Wk High: $ 65.00
Volume (M$): $ 0 52 Wk Avg: $51.64
Open: $59.47 52 Wk Low: $30.81



 Market Capitalization (Millions $) 8,541
 Shares Outstanding (Millions) 144
 Employees 507
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1,064
 Cash Flow (TTM) (Millions $) -86
 Capital Exp. (TTM) (Millions $) 15

Business Description


Vaxcyte Inc is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases. The company utilizes its comprehensive understanding of bacterial pathogens and immunology to develop vaccines that address significant unmet medical needs. Vaxcyte aims to protect people of all ages, from infants to adults, against a range of infectious diseases. Their vaccines are designed to provide long-lasting protection, improve public health, and reduce the burden of infectious diseases globally. Vaxcyte is committed to advancing vaccine research and development to make a significant impact on global healthcare.


   Company Address: 825 Industrial Road San Carlos 94070 CA
   Company Phone Number: 837-0111   Stock Exchange / Ticker: NASDAQ PCVX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IBRX        0.73% 
IVVD   -4.36%    
MRNA   -1.18%    
NVAX   -6.62%    
STRO   -17.48%    
VXRT   -1.02%    
• View Complete Report
   



Clinical Study

Vaxcyte’s VAX-31 Phase 2 Study A Promising Step Toward Enhanced Immune Defense Against Pneumococcal Disease in Infa...

Published Wed, Sep 3 2025 11:49 AM UTC

: The forefront of pediatric immunization strategies is highlighted through Vaxcyte’s recent announcement regarding the advancement of its VAX-31 Infant Phase 2 Dose-Finding Study. With the initial participants now receiving the optimized doses of VAX-31, the study aims to determine the most effective dosing regimen for eliciting robust immune responses in infants against ...
Shares

Vaxcyte Raises $1.5 Billion in Public Offering to Advance Vaccine Innovation,

Published Fri, Sep 6 2024 8:05 PM UTC

Vaxcyte Raises $1.5 Billion in Public Offering to Advance Vaccine Innovation
Vaxcyte, a clinical-stage vaccine innovation company, has announced the closing of a $1.5 billion public offering, including the full exercise of underwriters option to purchase additional shares. This successful fundraising effort will support the company s mission of engineering high-fidelity...
Financing Agreement

Vaxcyte Announces Pricing of $1.3 Billion Public Offering, Setting Stage for Accelerated Innovation and Financial Growth.

Published Thu, Sep 5 2024 3:59 AM UTC


Introduction
Vaxcyte, Inc. a leading clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases, has recently declared the pricing of an underwritten public offering of common stock and pre-funded warrants. The offering, totaling approximately $1.3 billion, highlights Vaxcytens commitment to expanding its rese...
Shares

Vaxcyte, Inc. Launches $1.0 Billion Offering to Drive Vaccine Innovation and Benefit Shareholders,

Published Tue, Sep 3 2024 8:02 PM UTC

Vaxcyte, Inc. Commences $1.0 Billion Common Stock and Pre-Funded Warrants Offering
SAN CARLOS, Calif. Sept. 03, 2024 - Vaxcyte, Inc. (Nasdaq: PCVX), a leading clinical-stage vaccine innovation company, announced today the commencement of an underwritten public offering of $1.0 billion worth of its common stock and pre-funded warrants. This strategic move reflects Vaxcyte...
Clinical Study

Vaxcyte’s 31-Valent Pneumococcal Vaccine VAX-31 Shows Strong Immune Response in Phase 1/2 Study for Older Adults,...

Published Tue, Sep 3 2024 11:08 AM UTC

In a significant advancement for public health, Vaxcyte has announced encouraging topline data from its Phase 1/2 clinical study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed for adults aged 50 and older. The data reveal that VAX-31 elicits strong opsonophagocytic activity (OPA) immune responses across all 31 serotypes tested, showcasing its potent...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.1
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.68
Working Capital Ratio 0.92
Leverage Ratio (MRQ) 0.14
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.01 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 1.27 $
Book Value 19.09 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,099,134
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.